Medical biotech in Poland is having a Goldilocks moment. Its companies are hot enough to drive a significant local ecosystem, but not so numerous that competition for public cash or talent is cut-throat. Yet there is also room for improvement, with the coverage and management of public funding seen as flawed, smart private investment scarce, academic researchers often out of synch with commercial needs and a shortage of the clinical development and regulatory skills that are needed to take drugs through to the market.
/PRNewswire/ Molecure S.A. ("Molecure": WSE: MOC) a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and.
Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Molecure S.A. ("Molecure": WSE: MOC) a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and.
Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.